[Form 4] Hilton Worldwide Holdings Inc. Insider Trading Activity
Form 4 summary — Hilton Worldwide (HLT): Reporting person Christian H. Charnaux (Executive Vice President & Chief Development Officer) filed a Form 4 reporting equity awards dated 08/05/2025 and filed 08/06/2025. All reported transactions are acquisitions (grants) with reported price $0.
Grants reported:
- 2,594 RSUs under the Hilton 2017 Omnibus Incentive Plan; vest in two equal annual installments beginning 08/05/2026.
- 9,609 RSUs under the Hilton 2017 Omnibus Incentive Plan; vest in four equal annual installments beginning 08/05/2026.
- Employee stock option for 7,085 shares; exercise price $260.15; vests in three equal annual installments beginning 08/05/2026; expiration 08/05/2035.
Filing details: Form filed by one reporting person; signature by attorney-in-fact James O. Smith dated 08/06/2025. Reported beneficial ownership following the transactions is shown as 6,451, 16,060, and 7,085 for the respective items.
- None.
- None.
Insights
TL;DR: Routine executive equity grants reported; limited immediate market impact absent larger disclosure or material size relative to outstanding shares.
The Form 4 documents acquisition-type awards to an officer of Hilton (HLT) dated 08/05/2025: two RSU grants (2,594 and 9,609 units) and an employee stock option for 7,085 shares at a $260.15 exercise price. Vesting schedules begin 08/05/2026 and the option expires 08/05/2035. These are granted under the Hilton 2017 Omnibus Incentive Plan and are reported as price $0, indicating compensation awards rather than open-market purchases. Investors typically view such filings as compensation-related rather than immediate liquidity events.
TL;DR: Multi-year vesting structure suggests retention-focused awards; monitor vesting timelines and potential future dilution.
The report shows time-based equity awards with staggered vesting: RSUs in two- and four-year installment structures and an option vesting over three years. All vesting commences 08/05/2026, tying value realization to continued service. The option carries a defined exercise price of $260.15 and a ten-year-plus term to 08/05/2035. From a governance perspective, these disclosures clarify grant size, plan source, and vesting mechanics but do not disclose performance conditions or aggregate dilution impact.